Merck gets USFDA nod for neoadjuvant/ adjuvant Keytruda for resectable non-small cell lung cancer Ruchika Sharma17 Oct 2023 7:24 AM GMTThe approval marks the sixth NSCLC indication for KEYTRUDA.
Merck Keytruda met primary endpoint of disease free survival in certain patients with Muscle-Invasive Urothelial Carcinoma after surgery Ruchika Sharma10 Oct 2023 6:00 AM GMTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
Merck Sotatercept for pulmonary arterial hypertension gets USFDA priority review Ruchika Sharma30 Sep 2023 5:30 AM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted for...
Merck Keytruda plus Padcev improves survival in advanced or metastatic urothelial carcinoma Ruchika Sharma24 Sep 2023 10:00 AM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced positive topline results from the Phase 3 KEYNOTE-A39...
Setback: Merck-Eisai combination therapy fails in lung cancer studies Ruchika Sharma23 Sep 2023 8:51 AM GMTNew Jersy: Drugmakers Merck and Eisai said on Friday a combination of their cancer therapies did not prolong the lives of patients in two...
Merck gets USFDA priority review for Keytruda plus concurrent chemoradiotherapy for cervical cancer Ruchika Sharma21 Sep 2023 12:03 PM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
Merck Welireg get USFDA priority review for certain previously treated patients with Advanced Renal Cell Carcinoma Ruchika Sharma21 Sep 2023 9:18 AM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted and...
Merck gets positive EU CHMP opinion for Keytruda as adjuvant treatment for adults with Non-Small Cell Lung Cancer Ruchika Sharma18 Sep 2023 6:00 AM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency’s Committee for Medicinal...
Merck presents new analyses from Sotatercept studies for adults with pulmonary arterial hypertension Ruchika Sharma13 Sep 2023 8:00 AM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced new analyses from studies of sotatercept, Merck’s novel...
Gilead Sciences Trodelvy, Keytruda combo study demonstrates promising clinical activity in first-line Metastatic Non-Small Cell Lung Cancer Ruchika Sharma12 Sep 2023 9:00 AM GMTFoster City: Gilead Sciences, Inc. has announced promising early data from the global, open-label, Phase 2 EVOKE-02 study evaluating Trodelvy...
Merck, Portage Biotech collaborate to evaluate Portage's next-generation adenosine antagonists in combination with Keytruda in solid tumors Ruchika Sharma10 Sep 2023 6:00 AM GMTWestport: Portage Biotech Inc., a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in...
European Commission expands Merck Ervebo indication to include children 1 year of age and older Ruchika Sharma9 Sep 2023 4:30 AM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Commission (EC) has approved an expanded...
